Drug intelligence / Profile preview

NP-4

Development stage: Preclinical
Lead developer: Nacuity Pharmaceuticals
Modality: Small Molecules
Administration: Intravitreal

Overview

NP-4 is a preclinical-stage small molecule antioxidant being developed by Nacuity Pharmaceuticals. It is formulated as an intravitreal implant for the treatment of age-related macular degeneration (AMD) and Stargardt disease. The drug's mechanism of action involves countering oxidative stress and acting on glutathione-related pathways to protect retinal tissues from oxidative damage. As an intravitreal implant, it is intended to provide localized, sustained delivery of the antioxidant payload directly to the retina to slow the progression of degenerative ocular diseases.

Beyond the preview

Go deeper on NP-4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NP-4.

Explore the full profile